Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 404

1.

Hospitalization Rates and Outcomes among Persons Living with HIV in the Southeastern United States, 1996-2016.

Davy-Mendez T, Napravnik S, Wohl DA, Durr AL, Zakharova O, Farel CE, Eron JJ.

Clin Infect Dis. 2019 Oct 22. pii: ciz1043. doi: 10.1093/cid/ciz1043. [Epub ahead of print]

PMID:
31637434
2.

PD-1HI T cells are associated with lower hiv-specific immune responses despite long-term antiretroviral therapy.

Macatangay BJC, Gandhi RT, Brad Jones R, Mcmahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR; ACTG A5321 Team.

AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002406. [Epub ahead of print]

PMID:
31634201
3.

Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis.

Poteat T, Hanna DB, Rebeiro PF, Klein M, Silverberg MJ, Eron JJ, Horberg MA, Kitahata MM, Mathews WC, Mattocks K, Mayor A, Rich AJ, Reisner S, Thorne J, Moore RD, Jing Y, Althoff KN; North American AIDS Cohort Collaboration On Research and Design of the International Epidemiology Databases to Evaluate AIDS.

Clin Infect Dis. 2019 Apr 23. pii: ciz322. doi: 10.1093/cid/ciz322. [Epub ahead of print]

PMID:
31573601
4.

Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma.

Nelson JAE, de Paris K, Ramirez C, Edmonds A, Mollan KR, Bay CP, Compliment K, Herold BC, Anastos K, Minkoff H, Kassaye S, Seidman DL, French AL, Golub ET, Sheth AN, Ochsenbauer C, Swanstrom R, Eron JJ, Adimora AA.

AIDS. 2019 Sep 2. doi: 10.1097/QAD.0000000000002373. [Epub ahead of print]

PMID:
31483374
5.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.

Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, DeJesus E, Petrovic R, Luo D, Van Landuyt E, Lathouwers E, Nettles RE, Brown K, Wong EY.

AIDS Res Ther. 2019 Aug 29;16(1):23. doi: 10.1186/s12981-019-0235-1.

6.

Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).

Feinstein MJ, Nance RM, Delaney JAC, Heckbert SR, Budoff MJ, Drozd DR, Burkholder GA, Willig JH, Mugavero MJ, Mathews WC, Moore RD, Eron JJ, Napravnik S, Hunt PW, Geng E, Hsue P, Peter I, Lober WB, Crothers K, Grunfeld C, Saag MS, Kitahata MM, Lloyd-Jones DM, Crane HM.

BMC Med. 2019 Jul 31;17(1):149. doi: 10.1186/s12916-019-1385-7.

7.

Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.

Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJC, Lalama C, Rinaldo C Jr, Collier A, Godfrey C, Hogg E, Hensel C, Eron JJ, Mcmahon DK, Mellors JW, Tebas P, Gandhi RT; A5321 Study Team.

J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e27-e31. doi: 10.1097/QAI.0000000000002124.

PMID:
31335587
8.

Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, Hogg E, Vecchio A, Mellors JW.

J Clin Invest. 2019 Jul 15;129(8):3339-3346. doi: 10.1172/JCI127413. eCollection 2019 Jul 15.

9.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group.

Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4.

10.

Clones of infected cells arise early in HIV-infected individuals.

Coffin JM, Wells DW, Zerbato JM, Kuruc JD, Guo S, Luke BT, Eron JJ, Bale M, Spindler J, Simonetti FR, Hill S, Kearney MF, Maldarelli F, Wu X, Mellors JW, Hughes SH.

JCI Insight. 2019 Jun 20;4(12). pii: 128432. doi: 10.1172/jci.insight.128432. eCollection 2019 Jun 20.

11.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

Gandhi RT, Tashima KT, Smeaton LM, Vu V, Ritz J, Andrade A, Eron JJ, Hogg E, Fichtenbaum CJ; ACTG A5241 study team.

J Infect Dis. 2019 May 28. pii: jiz281. doi: 10.1093/infdis/jiz281. [Epub ahead of print]

PMID:
31135883
12.

Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Crane HM, Nance RM, Heckbert SR, Ritchings C, Rosenblatt L, Budoff M, Wood BR, Tirschwell DL, Kim HN, Mathews WC, Geng E, Moore RD, Hunt PW, Eron JJ, Burkholder GA, Drozd DR, Chow FC, Becker KJ, Zunt JR, Ho EL, Kalani R, Huffer A, Whitney BM, Saag MS, Kitahata MM, Delaney JAC.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):e141-e147. doi: 10.1097/QAI.0000000000002071.

13.

Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077.

Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, Cohen MS, Currier JS.

Clin Infect Dis. 2019 May 24. pii: ciz439. doi: 10.1093/cid/ciz439. [Epub ahead of print]

PMID:
31125395
14.

Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.

Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-577. doi: 10.1097/QAI.0000000000002075.

15.

Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.

Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; ACTG 5321 Team.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599. doi: 10.1097/QAI.0000000000002080.

PMID:
31045647
16.

HIV-1 Phylodynamics to Detect and Characterize Active Transmission Clusters in North Carolina.

Dennis AM, Hué S, Billock R, Levintow S, Sebastian J, Miller WC, Eron JJ.

J Infect Dis. 2019 Apr 27. pii: jiz176. doi: 10.1093/infdis/jiz176. [Epub ahead of print]

PMID:
31028702
17.

Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load.

Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM.

Clin Infect Dis. 2019 Apr 17. pii: ciz299. doi: 10.1093/cid/ciz299. [Epub ahead of print]

PMID:
30994900
18.

Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia.

Hudson FP, Mulenga L, Westfall AO, Warrier R, Mweemba A, Saag MS, Stringer JS, Eron JJ, Chi BH.

Antivir Ther. 2019;24(4):291-300. doi: 10.3851/IMP3299.

PMID:
30977467
19.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

20.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA.

Stat Med. 2019 Jun 15;38(13):2428-2446. doi: 10.1002/sim.8120. Epub 2019 Mar 18.

PMID:
30883859

Supplemental Content

Support Center